SEARCH

Current Edition

cervical cancer

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical …

Continue Reading →